Chandler Capital

Chandler Capital

Expertise: Technology, Pharmaceutical, Energy, GARP

Chandler Capital is the work of Ian Hartana and Vayun Chugh.

Ian Hartana is a self-taught investor whose work has been featured on Seeking Alpha under the organization AlmaStreet Capital. Being on the student advisory board of the Young Investors Society, he is a long-time advocate for the advancement of financial literacy and has competed on the international level in multiple competitions. In his free time, he enjoys exploring the intersection between behavioral science and economics through writing on the platform Medium and is currently working as an intern at a small venture capital firm.

Vayun Chugh is also a self-taught investor and is both an editor and writer for AlmaStreet Capital. He is the president of his school’s finance club alongside Ian Hartana, and has also competed in multiple international competitions. Through his ongoing research in the medical field, Vayun has developed a deep understanding of the pharmaceutical industry and knows the characteristics of an undervalued company.

Ian and Vayun’s expertise lies in finding value in undervalued companies in the tech, pharmaceutical, and energy sectors which have the potential for growth at a reasonable price. They have a long-term investment horizon and consider ESG as an increasingly important factor in their research process.

Recent Articles

7 Undervalued Stocks to Buy Before Everyone Else

Buy these undervalued stocks while they trade at a significant discount compared to their intrinsic valuations.

7 Undervalued Stocks Poised for Explosive Growth in Q4

these 7 undervalued stocks are working toward high growth plans for the coming quarter. You can't miss out on them.

7 Innovator Stocks Primed for Exceptional Growth

As the market continues to rebound, investors should keep an eye on these companies at the forefront of innovation. They stand poised to surge ahead of their competition in terms of revenue and earnings.

3 Stocks That Could Beat the Russell 2000

Stocks with strong financials and growth, positioned for upsides beating indexes. Check out the stocks that could beat the Russell 2000.

Ticking Time Bombs: 3 Biotech Stocks to Dump Before the Damage Is Done

Investors should do their due diligence before investing in these three risky, unreliable and unprofitable biotech stocks.